MAP2K7 and neoplasm: Combinatorial inhibition of KRASG12C and mTORC1/2 or MEK and mTROC1/2 however suppressed tumor growth in PDAC in vitro models and in vivo experiments (Brown et al., 2020), identifying another potential targeted combination to overcome resistance mechanisms.